Get the Stockscreener App
0.615
4.17%
0.0246
Relmada Therapeutics Inc stock is traded at $0.615, with a volume of 140.80K.
It is up +4.17% in the last 24 hours and down -2.38% over the past month.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
See More
Previous Close:
$0.5904
Open:
$0.598
24h Volume:
140.80K
Relative Volume:
0.27
Market Cap:
$20.41M
Revenue:
-
Net Income/Loss:
$-98.79M
P/E Ratio:
-0.1881
EPS:
-3.27
Net Cash Flow:
$-51.66M
1W Performance:
-3.97%
1M Performance:
-2.38%
6M Performance:
+80.83%
1Y Performance:
-82.92%
1-Day Range:
$0.59
$0.6189
1-Week Range:
$0.5898
$0.6664
52-Week Range:
$0.2404
$3.98
Relmada Therapeutics Inc Stock (RLMD) Company Profile
Name
Relmada Therapeutics Inc
Sector
Industry
Phone
646 876 3459
Address
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
Compare RLMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 3.03 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
0.63 | 862.34M | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.21 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.83 | 121.44M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1478 | 322.13M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
1.8399 | 0 | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-24 | Downgrade | Mizuho | Outperform → Neutral |
| Sep-17-24 | Upgrade | Jefferies | Hold → Buy |
| Jun-05-24 | Downgrade | Goldman | Neutral → Sell |
| Oct-14-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-14-22 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-14-22 | Downgrade | Truist | Buy → Hold |
| Oct-13-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-18-21 | Initiated | Mizuho | Buy |
| May-20-21 | Resumed | Goldman | Buy |
| Oct-28-20 | Downgrade | Goldman | Buy → Neutral |
| Jul-14-20 | Initiated | Oppenheimer | Outperform |
| May-04-20 | Initiated | SunTrust | Buy |
| Apr-21-20 | Initiated | Goldman | Buy |
| Jan-27-20 | Initiated | Jefferies | Buy |
| Jan-10-20 | Initiated | SVB Leerink | Outperform |
| Dec-16-19 | Initiated | Guggenheim | Buy |
View All
Relmada Therapeutics Inc Stock (RLMD) Latest News
Is a relief rally coming for Relmada Therapeutics Inc. holdersIntraday Price Forecast Using Volume Models - Newser
What’s next for Relmada Therapeutics Inc. stock priceFree Early Entry Tips With Low Risk Zone - Newser
Published on: 2025-08-04 12:29:06 - metal.it
Will a bounce in Relmada Therapeutics Inc. offer an exitWeekly Setup Summary for Risk Controlled Trades - Newser
What are the latest earnings results for Relmada Therapeutics Inc.Get alerts on top growth stocks daily - Jammu Links News
Why Relmada Therapeutics Inc. stock attracts strong analyst attentionFree Alert Feed for Momentum Based Picks - Newser
Advanced analytics toolkit walkthrough for Relmada Therapeutics Inc.Free Community Entry Consensus Trade Ideas - Newser
What makes Relmada Therapeutics Inc. stock price move sharplyMarket Downturn Defense Strategy Analysis - Newser
Using portfolio simulators with Relmada Therapeutics Inc. includedShort-Term Stock Trend Forecast Guide - Newser
What catalysts could drive Relmada Therapeutics Inc. stock higher in 2025Unlock powerful trading signals for profits - Jammu Links News
How volatile is Relmada Therapeutics Inc. stock compared to the marketRobust investment performance - Jammu Links News
How does Relmada Therapeutics Inc. compare to its industry peersBuild a diversified portfolio for steady growth - Jammu Links News
What institutional investors are buying Relmada Therapeutics Inc. stockInvest in stocks with strong fundamentals - Jammu Links News
What analysts say about Relmada Therapeutics Inc. stockInvest in stocks with long-term growth potential - Jammu Links News
What drives Relmada Therapeutics Inc. stock priceCapitalize on emerging market opportunities - Jammu Links News
Real time breakdown of Relmada Therapeutics Inc. stock performanceOversold Reversal Picks with Buy Zone - Newser
Using fundamentals and technicals on Relmada Therapeutics Inc.Capital Secure Pattern Signal Analysis Sheet - Newser
What is the risk reward ratio of investing in Relmada Therapeutics Inc. stockAccess daily stock market expert updates - Jammu Links News
What are analysts’ price targets for Relmada Therapeutics Inc. in the next 12 monthsUnbelievable profit margins - Jammu Links News
How strong is Relmada Therapeutics Inc. company’s balance sheetInvest in stocks with strong fundamentals - Jammu Links News
Why is Relmada Therapeutics Inc. stock attracting strong analyst attentionStay informed with daily expert analysis - Jammu Links News
What are Relmada Therapeutics Inc. company’s key revenue driversStay informed with daily expert analysis - Jammu Links News
Relmada Therapeutics (RLMD.US) will release its earnings reports after the market closes on August 7th. - 富途牛牛
How to monitor Relmada Therapeutics Inc. with trend dashboardsSmart Trade Mapping with Entry Details - Newser
Building trade automation scripts for Relmada Therapeutics Inc.Free Safe Entry Stock Watch Suggestions - Newser
Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025 - The Manila Times
Relmada Therapeutics Sets Q2 Earnings Date: Key Updates Expected on Oncology and CNS Pipeline - Stock Titan
Relmada Therapeutics Inc. At Decision Level — Rebound or ResistanceReal Time Stock Movement Analysis Indicates Breakout - beatles.ru
Relmada Therapeutics (NASDAQ:RLMD) Shares Down 2.3% – Here’s What Happened - Defense World
Does Relmada Therapeutics Inc. stock perform well during market downturnsBeginner Investor Growth Plan For Every Investor - Jammu Links News
When is Relmada Therapeutics Inc. stock expected to show significant growthPost Market Outlook For Every Investor - Jammu Links News
Why Relmada Therapeutics Inc. stock attracts strong analyst attention Monthly Trade Result and Signal Summary - Newser
Why Relmada Therapeutics Inc. stock attracts strong analyst attention AI Screener Based Stock Summary Report - metal.it
Is it the right time to buy Relmada Therapeutics Inc. stockPhenomenal returns - Jammu Links News
What is the dividend policy of Relmada Therapeutics Inc. stockUnlock high-yield investment opportunities - Jammu Links News
Relmada Therapeutics Inc Stock (RLMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.24%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):